Helix Introduces Whole Exome+® Sequencing for Rare Genetic Conditions

Helix Announces Whole Exome+® Sequencing Launch

Helix, an industry leader in genomic technology, has recently introduced Whole Exome+® Sequencing (WES+), a cutting-edge diagnostic tool aimed at assisting patients suffering from undiagnosed developmental delays, neurological issues, and various rare genetic disorders. This innovative test combines multiple genomic analyses into a single, simple order, revolutionizing the way healthcare providers approach genetic diagnostics.

A Comprehensive Approach to Genetic Diagnosis

The Whole Exome+® Sequencing test integrates four vital components:
1. Broad Exome Coverage: It evaluates 99% of clinically significant regions within the genome.
2. Mitochondrial Genome Analysis: Enhances the assessment of genetic disorders related to mitochondrial functions.
3. Genome-wide Digital Karyotype: This unique feature offers high-resolution chromosomal copy number analysis, providing a clearer understanding of chromosomal variations.
4. Combined Testing: Traditionally, mitochondrial tests are ordered separately; however, WES+ incorporates these alongside other assessments, simplifying the process for clinicians.

Available in proband-only, duo, and trio configurations, WES+ does not require providers to pre-select genes or panels; instead, clinical notes guide Helix's advanced analysis, prioritizing variants based on phenotype details submitted at the time of ordering.

Meeting Clinical Needs

Helix's latest offering reflects emerging trends in clinical practice recommendations. Major organizations, including the American College of Medical Genetics, are now advocating for exome or genome sequencing as the primary diagnostic method for individuals with conditions like unexplained developmental delays or autism spectrum disorders. This paradigm shift places WES+ at the forefront, promising quicker access to crucial genetic insights that may have previously taken years to uncover through conventional testing methods.

According to Dr. Cassie Hajek, Helix's Medical Director, many patients endure lengthy testing processes with inconclusive results. WES+ addresses this issue by providing a comprehensive view of genomic factors right from the initial consultation. This timely information can guide clinicians in adopting more effective management strategies for their patients.

The SOQO® Model: A Permanent Clinical Asset

Central to the WES+ framework is the Sequence Once, Query Often® (SOQO®) model. This innovative approach allows clinicians to establish a patient’s genomic data as a lasting clinical resource rather than viewing sequencing as a one-time event. As new genetic associations are identified, clinicians can re-analyze existing data without requiring fresh samples, streamlining the diagnostic process. Each WES+ order includes one complimentary reanalysis per year upon request, ensuring that patients remain at the cutting edge of genomic insights.

Smooth Integration with Healthcare Providers

WES+ can be ordered through Helix's provider portal and various electronic health record (EHR) systems, with further EHR integration planned as partnerships evolve. Helix collaborates with both national and regional health insurance providers, ensuring accessibility for a broad patient population, including those covered by Medicare and Medicaid. Financial assistance is also in place for qualifying patients, making genetic testing more financially viable.

As healthcare moves towards more personalized and precise approaches, Helix is committed to leveraging the power of genomics. By providing WES+, they aim to shorten the time to diagnosis for individuals grappling with rare genetic conditions, ultimately transforming patient outcomes and paving the way for future discoveries in the field.

For more details on ordering WES+ or to explore Helix's wide-ranging diagnostic portfolio, visit their official website.